SBIR/STTR Research Award
THERAPEUTIC VACCINE PLATFORM TO BOOST IMMUNE RESPONSES IN TUBERCULOSIS
Award amount
$599,471Program and phase
SBIR · Phase IAward year
2025Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- L2 DIAGNOSTICS LLC
- Proposal award date
- Not reported
- Contract end date
- Not reported
- UEI
- GKA7VH5LFR25
- Solicitation number
- PHS 2025-1
- Topic code
- 137
Research abstract
Therapeutic vaccine platform to boost immune responses in Tuberculosis
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
- A vaccine targeting mosquito metabolic pathways to eradicate malaria
- PfAg, a multivalent peptide vaccine against malaria
- A Point of Care Test for Babesia microti
- Novel Diagnostic Biomarker Discovery and Validation for Malaria
- A viral vector-based vaccine to induce humoral and cellular immune protection against Powassan virus in a tick transmission model
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- B-SMART - BROADLY NEUTRALIZING ANTIBODIES FOR SARNA MEDIATED ANTIVIRAL RESPONSE THERAPY
- EVALUATING HBVZ10-BASED THERAPIED FOR CCCDNA CLEARANCE: VIROLOGICAL FOUNDATION AND SYNERGISTIC COMBINATIONS
Research funding history
84 SBIR/STTR records share this UEI (1999–2025). Reported award amounts total $45,551,124. Reported amounts are not federal obligations.
Phases: Phase I, Phase II, Phase II – Direct to Phase II
Agencies: Department of Health and Human Services, Department of Defense